# Effect of C21 on Forearm Blood Flow

> **NCT05277922** · PHASE1 · COMPLETED · sponsor: **Vicore Pharma AB** · enrollment: 5 (actual)

## Conditions studied

- Study Vasodilatory Effects of C21

## Interventions

- **DRUG:** C21
- **DRUG:** Sodium Nitroprusside

## Key facts

- **NCT ID:** NCT05277922
- **Lead sponsor:** Vicore Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-28
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-05-18
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05277922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05277922, "Effect of C21 on Forearm Blood Flow". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05277922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*